Scalper1 News
Biotech Regeneron Pharmaceuticals got good news and bad news Friday morning as its drug Eylea outperformed the competition in a clinical trial, but it also got sued for patent infringement by Amgen over its cholesterol drug. Investors focused on the positive, as Regeneron Pharmaceuticals (REGN) stock was up 9% in morning trading on the stock market today, above 372. Earlier, Regeneron stock touched an all-time high of 375.90. The trial made a Scalper1 News
Scalper1 News